Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Invacare acquisitions

This article was originally published in The Gray Sheet

Executive Summary

Invacare acquisitions: Home medical equipment firm expands presence in U.K. through $5.1 mil. cash purchase of Bencraft Limited, a Birmingham, England-based manufacturer of powered and manual wheelchairs. Bencraft had about $10 mil. in sales for its fiscal year ended March 21. Invacare also recently purchased Patient Solutions, Inc., which has a four-modality infusion pump that gives Invacare "a totally new product line that many of our existing DME [durable medical equipment]/respiratory provider customers will purchase as they diversify into home infusion therapy." PSI's pump can provide intravascular feeding, intermittent antibiotic therapy, patient-controlled analgesia and chemotherapy. Privately held with about $1-2 mil. in annual sales, PSI will continue to operate out of its San Diego headquarters under current management led by President Dave Davis...

You may also be interested in...



Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.

UsernamePublicRestriction

Register

MT004299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel